Last updated on June 2018

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye


Brief description of study

This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.

Detailed Study Description

The T&E dosing regimen for nAMD has emerged as a preferred regimen for many treating physicians aiming at maximizing outcomes by proactively treating the subject at each visit and by extending the treatment interval (if extension criteria are met), thus limiting visits, monitoring, and injections.

To this day, there is limited evidence available addressing the question of what are useful intervals for treating and monitoring, how do they differ among subjects, and how are retreatment criteria applied to achieve long-term desirable outcomes in real-life practice. This study is designed to evaluate the optimal use, efficacy, and safety of the T&E regimen with intravitreal aflibercept in subjects with nAMD.

Clinical Study Identifier: NCT02581891

Contact Investigators or Research Sites near you

Start Over

Strathfield, Australia

Sydney, Australia

Westmead, Australia

East Melbourne, Australia

Launceston, Australia

Hamilton, ON Canada

Ottawa, ON Canada

Boisbriand, QC Canada

Creteil Cedex, France

Nice cedex 1, France

Freiburg, Germany

Hannover, Germany

Bonn, Germany

Sulzbach, Germany

Chemnitz, Germany

Berlin, Germany

Budapest, Hungary

Debrecen, Hungary

Pecs, Hungary

Szombathely, Hungary

Roma, Italy

Milano, Italy

Padova, Italy

Oviedo, Spain

Madrid, Spain

Zaragoza, Spain

Canterbury, United Kingdom

Bristol, United Kingdom

Liverpool, United Kingdom

London, United Kingdom

Oxford, United Kingdom

Tübingen, Germany

Köln, Germany